TABLE 2

Multivariable logistic regression analysis for all-cause in-hospital mortality

	Adjusted OR	95% CI	p-value
Body mass index kg·m⁻²
<18.5	1.25	1.10–1.42	0.001
18.5–22.9	Reference
23.0–24.9	0.92	0.82–1.02	0.122
25.0–29.9	0.98	0.88–1.09	0.706
≥30.0	0.71	0.54–0.94	0.016
Age years
15–60	Reference
61–70	1.86	1.55–2.29	<0.001
71–80	2.32	1.94–2.77	<0.001
≥81	2.98	2.47–3.59	<0.001
Sex
Female	Reference
Male	1.37	1.23–1.53	<0.001
Hugh–Jones dyspnoea class
1	Reference
2	1.20	0.94–1.52	0.137
3	1.41	1.12–1.78	0.003
4	2.02	1.62–2.51	<0.001
5	4.91	4.02–6.01	<0.001
Japan Coma Scale score
0-digit (alert)	Reference
1-digit (dull)	1.19	1.02–1.39	0.024
2- or 3-digit (somnolence or coma)	0.97	0.73–1.29	0.822
Charlson comorbidity index
0	Reference
1	0.87	0.77–0.98	0.027
2	1.23	1.09–1.38	0.001
3–5	1.06	0.89–1.28	0.503
≥6	2.60	2.12–3.19	<0.001
Smoking index pack-years
0	Reference
1–19	0.84	0.72–0.98	0.026
20–39	0.82	0.73–0.93	0.002
40–59	0.77	0.67–0.89	<0.001
≥60	0.78	0.68–0.90	0.001
Intensive care unit admission	0.78	0.67–0.91	0.001
Emergency unit admission	0.79	0.67–0.94	0.007
Academic hospital	0.70	0.63–0.78	<0.001
Lung cancer	2.28	1.94–2.69	<0.001
COPD	0.77	0.63–0.94	0.010
Chronic heart disease	1.05	0.91–1.22	0.484
Chronic renal failure	1.65	1.26–2.16	<0.001
Diabetes mellitus	0.94	0.85–1.03	0.177
Pneumonia	0.97	0.81–1.16	0.724
Pulmonary embolism	0.83	0.48–1.45	0.516
Noradrenaline	0.80	0.62–1.03	0.084
Azithromycin	0.79	0.69–0.89	0.001
Sulfamethoxazole trimethoprim	0.42	0.39–0.46	<0.001
Cyclophosphamide (intravenous)	4.20	3.59–4.91	<0.001
Cyclophosphamide (oral)	2.84	1.99–4.06	<0.001
Cyclosporin	2.31	1.99–2.68	<0.001
Tacrolimus	0.89	0.64–1.22	0.688
Azathioprine	1.77	1.21–2.60	0.003
Pirfenidone	1.13	0.93–1.39	0.223
Nintedanib	0.76	0.57–1.01	0.063
Sivelestat sodium hydrate	1.33	1.13–1.55	<0.001
Thrombomodulin α	3.07	2.35–4.01	<0.001
Mechanical ventilation	4.01	3.54–4.53	<0.001
Haemodialysis	1.26	0.81–1.96	0.305
Tracheotomy	1.82	1.30–2.54	<0.001